AU2022271741A1 - Purification method of antibody composition - Google Patents

Purification method of antibody composition Download PDF

Info

Publication number
AU2022271741A1
AU2022271741A1 AU2022271741A AU2022271741A AU2022271741A1 AU 2022271741 A1 AU2022271741 A1 AU 2022271741A1 AU 2022271741 A AU2022271741 A AU 2022271741A AU 2022271741 A AU2022271741 A AU 2022271741A AU 2022271741 A1 AU2022271741 A1 AU 2022271741A1
Authority
AU
Australia
Prior art keywords
thr
gly
val
ser
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022271741A
Other languages
English (en)
Inventor
Stefan IARUSSO
Takayuki Yoshimori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiome Bioscience Inc
Original Assignee
Chiome Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiome Bioscience Inc filed Critical Chiome Bioscience Inc
Publication of AU2022271741A1 publication Critical patent/AU2022271741A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022271741A 2021-05-10 2022-05-06 Purification method of antibody composition Pending AU2022271741A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021079977 2021-05-10
JP2021-079977 2021-05-10
PCT/JP2022/019548 WO2022239704A1 (ja) 2021-05-10 2022-05-06 抗体組成物の精製方法

Publications (1)

Publication Number Publication Date
AU2022271741A1 true AU2022271741A1 (en) 2023-11-23

Family

ID=84029593

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022271741A Pending AU2022271741A1 (en) 2021-05-10 2022-05-06 Purification method of antibody composition

Country Status (10)

Country Link
US (1) US20240383945A1 (https=)
EP (1) EP4353734A4 (https=)
JP (1) JPWO2022239704A1 (https=)
KR (1) KR20240005771A (https=)
CN (1) CN117279929A (https=)
AU (1) AU2022271741A1 (https=)
CA (1) CA3219950A1 (https=)
IL (1) IL308169A (https=)
TW (1) TW202309062A (https=)
WO (1) WO2022239704A1 (https=)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS644947A (en) 1987-06-29 1989-01-10 Rohm Co Ltd Consecutive recording method for video tape recorder
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
EP1739089A4 (en) 2004-03-30 2007-05-02 Hiroshi Yanagisawa PROCESS FOR DISINTER SEPARATION
WO2008120801A1 (ja) 2007-04-02 2008-10-09 Kyowa Hakko Kirin Co., Ltd. アンチトロンビン組成物の製造方法
US9249182B2 (en) * 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
ES2665341T3 (es) * 2012-10-03 2018-04-25 Chiome Bioscience Inc. Anticuerpo anti-DLK-1 humana con actividad antitumoral in vivo
WO2014145744A1 (en) * 2013-03-15 2014-09-18 Alder Biopharmaceuticals, Inc. Antibody purification and purity monitoring
US20180327447A1 (en) * 2015-11-18 2018-11-15 Merck Patent Gmbh Improved protein separation in ion exchange chromatography
CA3127174A1 (en) * 2019-01-23 2020-07-30 Daiichi Sankyo Company, Limited Methods for purifying antibodies comprising of a process by using activated carbon materials
US20220177582A1 (en) * 2019-03-13 2022-06-09 Ichnos Sciences SA Non-consensus glycosylation of bispecific antibodies
JP2021079977A (ja) 2019-11-19 2021-05-27 凸版印刷株式会社 袋状容器の注出口ユニット

Also Published As

Publication number Publication date
CN117279929A (zh) 2023-12-22
CA3219950A1 (en) 2022-11-17
WO2022239704A1 (ja) 2022-11-17
TW202309062A (zh) 2023-03-01
EP4353734A1 (en) 2024-04-17
JPWO2022239704A1 (https=) 2022-11-17
EP4353734A4 (en) 2025-05-21
IL308169A (en) 2024-01-01
KR20240005771A (ko) 2024-01-12
US20240383945A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
AU2016381992B2 (en) Method for promoting efficiency of purification of Fc region-containing polypeptide
AU2016296321B2 (en) Anti-TfR antibodies and their use in treating proliferative and inflammatory disorders
AU2017255970B2 (en) Bispecific antibodies targeting EGFR and HER2
AU2016368469B2 (en) Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
US11926667B2 (en) Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
AU2021408214A9 (en) Interleukin-21 mutant and use thereof
AU2017256786B2 (en) Binding molecules specific for FcγGamma RIIA and uses thereof
Yazaki et al. Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications
AU2016426507B2 (en) PD-1 antibodies
AU2017236183B2 (en) Binding molecules to CD38 and PD-L1
AU2018206229B2 (en) A polypeptide linker for preparing multispecific antibodies
AU2019242559B2 (en) Monoclonal antibodies that bind to SSEA4 and uses thereof
IL312251A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AU2021301921B2 (en) Bispecific antibody and use thereof
AU2017273959B2 (en) ETAR antibody, pharmaceutical composition and use thereof
AU2020291487B2 (en) Bispecific antibody against alpha-syn/IGF1R and use thereof
AU2022273737A1 (en) Antigen-binding molecule
AU2022271741A1 (en) Purification method of antibody composition
CA3197930A1 (en) Relative unpaired glycans in antibody production methods
JP7762143B2 (ja) 抗体組成物を製造する方法
AU2022269145A1 (en) Fc mutant with altered binding to fc receptor
AU2022207252A9 (en) MULTISPECIFIC ANTIBODY BINDING TO ActRIIA, ActRIIB, AND Fn14
CA3233279A1 (en) Fc-gamma receptor ii binding and glycan content
CN105348388B (zh) 抗cd20抗原的抗体l3h3及其应用
HK1256088B (en) Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders